The estimated Net Worth of Louise Rodino Klapac is at least $10.3 Million dollars as of 21 June 2024. Dr Klapac owns over 6,250 units of Sarepta Therapeutics Inc stock worth over $9,542,330 and over the last 4 years he sold SRPT stock worth over $0. In addition, he makes $739,054 as Chief Scientific Officer and Head of R&D at Sarepta Therapeutics Inc.
Sign up
Dr D SRPT stock SEC Form 4 insiders trading
Dr has made over 2 trades of the Sarepta Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 6,250 units of SRPT stock worth $802,438 on 21 June 2024.
The largest trade he's ever made was exercising 6,250 units of Sarepta Therapeutics Inc stock on 21 June 2024 worth over $802,438. On average, Dr trades about 669 units every 63 days since 2020. As of 21 June 2024 he still owns at least 74,323 units of Sarepta Therapeutics Inc stock.
You can see the complete history of Dr Klapac stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Louise Rodino-Klapac Ph.D. biography
Dr. Louise Rodino-Klapac Ph.D. is the Chief Scientific Officer and Head of R&D at Sarepta Therapeutics Inc.
What is the salary of Dr D?
As the Chief Scientific Officer and Head of R&D of Sarepta Therapeutics Inc, the total compensation of Dr D at Sarepta Therapeutics Inc is $739,054. There are 7 executives at Sarepta Therapeutics Inc getting paid more, with Gilmore O'Neill having the highest compensation of $5,168,110.
How old is Dr D?
Dr D is 43, he's been the Chief Scientific Officer and Head of R&D of Sarepta Therapeutics Inc since . There are 16 older and no younger executives at Sarepta Therapeutics Inc. The oldest executive at Sarepta Therapeutics Inc is Hans Wigzell, 82, who is the Independent Director.
Insiders trading at Sarepta Therapeutics Inc
Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry und M Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.
What does Sarepta Therapeutics Inc do?
sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
What does Sarepta Therapeutics Inc's logo look like?
Complete history of Dr Klapac stock trades at Sarepta Therapeutics Inc
Sarepta Therapeutics Inc executives and stock owners
Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Gilmore O'Neill,
Executive Vice President, R&D and Chief Medical Officer -
William Ciambrone,
Executive Vice President - Technical Operations -
David Howton,
Executive Vice President, General Counsel, Secretary -
Alexander Cumbo,
Executive Vice President and Chief Commercial Officer -
Douglas Ingram,
President, Chief Executive Officer, Director -
Douglas S. Ingram,
Pres, CEO & Director -
Dr. Gilmore O'Neill M.D.,
Exec. Officer -
Dr. Louise Rodino-Klapac Ph.D.,
Chief Scientific Officer and Head of R&D -
Ian Michael Estepan,
Exec. VP & CFO -
William F. Ciambrone,
Exec. VP of Technical Operations -
M. Kathleen Behrens,
Independent Chairwoman of the Board -
Richard Barry,
Independent Director -
Hans Wigzell,
Independent Director -
Claude Nicaise,
Independent Director -
Mary Gray,
Independent Director -
John Martin,
Independent Director -
Joseph Bratica,
Interim Principal Financial and Accounting Officer -
Dr. Diane L. Berry,
Sr. VP of Global Health Policy and Gov. & Patient Affairs -
Alison Nasisi,
Chief People Officer & VP -
Ryan E. Brown,
Sr. VP, Gen. Counsel & Corp. Sec. -
Mary Jenkins,
Sr. Mang. of Investor Relations -
Michael W Bonney,
Director -
Ben Gil Price,
Director -
Catherine Stehman Breen,
SVP, Chief Medical Officer -
Jayant Aphale,
SVP Technical Operations -
Jean Paul Kress,
Director -
William Alden Goolsbee,
Director -
Shamim Ruff,
SVP, Chief Regulatory Affairs -
Sandesh Mahatme,
EVP, CFO & CBO -
Guriqbal S. Basi,
SVP, Chief Scientific Officer -
Michael A Jacobsen,
VP of Finance and PAO -
Anthony Martignetti,
-
Nishan Garabedian Christopher,
President and CEO -
Anthony R Chase,
Director -
John Hodgman,
Director -
Arthur M Krieg,
SVP, Chief Scientific Officer -
Edward M. Md Kaye,
SVP & Chief Medical Officer -
Ian Michael Estepan,
Chief Financial Officer -
Ryan Edward Brown,
EVP, General Counsel -
Louise Rodino Klapac,
Head of R&D, CSO -
Bilal Arif,
Chief Tech Ops Officer -
Stephen Mayo,
-
Kathryn Jean Boor,
-
Dallan Murray,
Chief Customer Officer